Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Locus Biosciences has raised $19 million in a series A funding round to develop antibiotics with CRISPR. While most gene-editing companies are working with CRISPR/Cas9 to make fine-tuned cuts in human DNA, Research Triangle Park, N.C.-based Locus is using a version of CRISPR, called CRISPR/Cas3, that acts more like a chainsaw, tearing up precisely targeted bacterial DNA. Investors include Tencent Holdings, Abstract Ventures, and the North Carolina Biotechnology Center.
This article has been sent to the following recipient: